Consistent with their respective in vitro profiles, baseline polymorphisms in NS3 or NS5A had no impact on treatment outcomes with the glecaprevir-pibrentasvir regimen, and there were no virologic failures among DAA-naive GT2-infected patients without cirrhosis or with compensated cirrhosis in the CERTAIN-1 and CERTAIN-2 studies. This evidence concerns the gene KRAS and Cirrhosis.